One of the most compelling ideas emerging from regenerative medicine is that the environment surrounding our cells may matter almost as much as the therapies we introduce into it.
Blood plasma is much more than the liquid portion of blood. It is a dynamic biological environment containing proteins, antibodies, hormones, metabolites, inflammatory mediators, signaling molecules, and products of oxidative and cellular stress. That environment changes throughout life and can be influenced by inflammation, immune dysfunction, metabolic health, disease, medications, lifestyle, and other factors.
Research on young plasma has increasingly highlighted the importance of this circulating environment. Early studies focused on whether younger blood contained beneficial “youth factors” that might influence repair and regeneration. Over time, another possibility emerged: some of the biological differences associated with aging may involve not only the loss of beneficial factors, but also the accumulation of circulating factors that may interfere with healthy cellular function.
In other words, the opportunity may involve not only what we add, but also what we remove.
A Different Approach to the Circulating Environment
This idea is central to the PUR-FORM approach.
Rather than transfusing whole plasma from a young donor, we are interested in a more selective question:
Can we remove some potentially unfavorable elements from the existing plasma environment, rebuild essential plasma functions in a controlled way, and then introduce regenerative signals into that newly remodeled environment?
Whole young-donor plasma may sound appealing, but plasma is extraordinarily complex. A recipient does not receive only the components that might be considered desirable. They receive the donor’s entire plasma environment, including antibodies, immune proteins, coagulation factors, metabolites, signaling molecules, and thousands of other biological constituents.
Even a healthy young donor has a unique biological history. Plasma transfusion also carries recognized risks, including allergic and transfusion reactions and, less commonly, serious complications. The FDA has not established young-donor plasma as a treatment for normal aging or age-related conditions.
PUR-FORM therefore takes a different approach.
The objective is not to give someone “young blood.” Instead, we are exploring whether we can create selected characteristics associated with a healthier, more youthful circulating environment without transfusing whole young-donor plasma and without unnecessarily introducing its biological complexity and transfusion-related risks.
We refer to this concept as plasma-environment remodeling.
The PUR-FORM Sequence
The strategy follows a deliberate sequence:
MODULATE → SUPPORT → REMOVE → REPLACE → REGENERATE
The PUR-FORM plasma-environment remodeling sequence.
MODULATE: Preparing the Biological Environment With EBO2
For many patients, the process begins with EBO2, an extracorporeal blood procedure that exposes blood to controlled ozone during processing.
Ozone-based blood therapies have been studied for potential effects on redox signaling, antioxidant responses, oxygen metabolism, and inflammatory pathways. Evidence varies by indication and treatment method, and many proposed applications remain investigational.
Within the PUR-FORM protocol, however, the key point is EBO2’s position in the sequence. It precedes therapeutic plasma exchange, beginning to influence the patient’s existing redox and inflammatory environment before the removal stage.
Conceptually, EBO2 initiates the preparation of the biological environment.
SUPPORT: Individualized IV and Metabolic Support
The next stage may include individualized IV and metabolic support tailored to the patient’s medical history, laboratory findings, treatment goals, and overall clinical plan.
Rather than applying the same supportive therapy to every patient, this part of the protocol can be tailored while preserving the broader sequence leading to therapeutic plasma exchange.
REMOVE: Therapeutic Plasma Exchange and Biological Subtraction
The next major step is therapeutic plasma exchange, or TPE, commonly referred to as plasmapheresis.
During TPE, blood is separated into its cellular and plasma components. A portion of the patient’s plasma is removed, the blood cells are returned, and an appropriate replacement fluid is administered.
Unlike a medication designed to affect a single target, plasma exchange can physically remove a broad range of circulating plasma constituents simultaneously.
Therapeutic plasma exchange already has established uses in conventional medicine, including selected autoimmune, neurologic, hematologic, and antibody-mediated conditions.
Within the PUR-FORM model, we are interested in an additional concept: biological subtraction.
If the circulating environment contains inflammatory mediators, disease-associated antibodies, oxidatively modified proteins, or other plasma-associated factors that may interfere with normal cellular signaling and repair, removing and diluting some of those factors may create a different biological starting point.
This is where the connection to young-plasma research becomes particularly interesting.
We are not suggesting that plasma exchange makes someone’s blood “young.” Rather, the hypothesis is that removing and diluting selected components of the existing plasma environment may allow us to pursue some of the potentially desirable characteristics associated with a healthier, more youthful circulation without transfusing another person’s whole plasma.
But removing plasma is only half of the process.
What we put back also matters.
REPLACE: Why Albumin May Matter
Albumin is commonly used as a replacement fluid during therapeutic plasma exchange because it helps maintain blood volume and oncotic pressure.
Yet albumin is much more than a volume expander.
It is the most abundant protein in human plasma and transports hormones, fatty acids, medications, metals, bilirubin, and many other molecules. Albumin also plays an important role in antioxidant and redox biology.
Like other proteins in the body, albumin can change over time. As it circulates, it may undergo oxidation, glycation, and other biochemical modifications associated with oxidative and metabolic stress. These changes can affect some of its biological properties.
This raises an intriguing question:
If we are rebuilding the plasma environment after therapeutic plasma exchange, could the biochemical quality of the albumin used for replacement matter as well as the quantity?
Human Umbilical Cord Blood-Derived Albumin
This is where human umbilical cord blood-derived albumin becomes particularly interesting in the PUR-FORM approach.
Cord blood represents a developmentally young biological environment. Albumin originating from that environment has not spent decades circulating through an adult body and accumulating the same history of oxidative, metabolic, inflammatory, and environmental exposures.
In selected PUR-FORM protocols, a highly purified cord-blood-derived albumin fraction may therefore be incorporated into the albumin replacement strategy.
Characterization information supplied for the preparation describes a highly concentrated, acellular, and leukocyte-depleted albumin product with a predominantly reduced albumin profile and low reported levels of oxidative and glycation-related modification.
These characteristics do not establish a clinical benefit of rejuvenation.
Rather, they raise an interesting scientific question:
Could albumin from a developmentally young source provide a different biochemical starting point when reconstructing the plasma environment after therapeutic plasma exchange?
This distinction is important because it separates the PUR-FORM concept from the mere administration of young plasma.
Whole-donor plasma is an extraordinarily complex biological mixture from another person. An albumin-based reconstruction strategy is much more selective.
The goal is to remove what may be unfavorable, replace what the body needs, and explore whether the biochemical quality of what we use to rebuild the plasma environment matters.
REGENERATE: Introducing Regenerative Signals
Once the circulating environment has been remodeled, the final stage is REGENERATE.
For selected patients, this may involve mesenchymal stromal cells, or MSCs, together with extracellular vesicles commonly referred to as exosomes.
Much of the scientific interest in MSCs today focuses on their ability to communicate with the immune system and surrounding tissues, rather than simply becoming replacement tissue themselves.
MSCs release a wide range of biological signals and have been investigated for potential roles in immune regulation, inflammatory signaling, vascular support, cellular survival, and tissue repair.
Exosomes and other extracellular vesicles are another part of this communication system.
These tiny membrane-bound particles can carry proteins, lipids, RNA, and other molecular signals between cells. A simple way to think about them is as biological packages that carry information from one cell to another.
MSCs naturally release extracellular vesicles as part of their communication with their environment, and researchers are investigating how these signals may contribute to some of the biological effects associated with MSCs.
Why Sequencing Matters
The placement of MSCs and exosomes after plasma exchange is intentional.
There is a practical reason. Administering circulating cellular or extracellular products immediately before plasma exchange could result in components of those therapies being removed.
But there is also a more interesting biological question:
Could regenerative therapies function differently depending on the environment into which they are introduced?
That question brings the entire PUR-FORM strategy together.
If the circulating environment contains significant inflammatory signaling, disease-associated antibodies, oxidatively modified proteins, or other unfavorable plasma-associated factors, simply adding regenerative therapies does not necessarily change the environment those therapies must operate in.
The PUR-FORM philosophy is therefore to prepare the environment first, then introduce regenerative signaling.
Bringing Advanced Modalities Together
Another distinguishing aspect of the PUR-FORM approach is its ability to coordinate these advanced modalities within a single clinical setting.
EBO2, therapeutic plasma exchange, individualized IV therapy, specialized albumin replacement strategies, and regenerative therapies such as MSCs and extracellular vesicles each require specialized equipment, clinical expertise, and medical oversight.
It is uncommon to find these modalities available together within a single practice and organized into a single, intentionally sequenced protocol.
That integration is important because the PUR-FORM approach is not simply about offering a collection of individual therapies. It is about how those therapies are coordinated and sequenced.
Bringing these capabilities together enables the clinical team to oversee the progression from modifying the circulating environment, to removing and
rebuilding portions of it, and finally to introducing regenerative therapies, all within a single coordinated continuum of care.
Prepare the Environment First
The entire concept can be expressed simply:
Remove what may be unfavorable, rebuild what is essential, and then introduce regenerative signals into a better-prepared biological environment.
This does not mean PUR-FORM is creating “young blood,” nor does it mean that therapeutic plasma exchange, cord-blood-derived albumin, MSCs, or exosomes have been proven to reverse aging.
The individual components have varying degrees of scientific and clinical evidence, and the combined PUR-FORM protocol remains an evolving clinical strategy.
The potential advantages of cord-blood-derived albumin in this setting, as well as many regenerative applications of MSCs and extracellular vesicles, remain under investigation.
The underlying question, however, is compelling.
Instead of simply asking what regenerative therapy should we put into the body, perhaps we should first ask:
What biological environment do we want that therapy to encounter?
That is the philosophy behind the PUR-FORM approach:
MODULATE → SUPPORT → REMOVE → REPLACE → REGENERATE
Prepare the environment first. Then create the opportunity for repair.
Dr. P
These statements have not been evaluated by the FDA.
